Christopher Del Nagro
About Christopher Del Nagro
Christopher Del Nagro serves as the Head of Translational Science and Biomarkers at Asher Biotherapeutics, bringing over 16 years of experience in drug development. He has held various positions in prominent companies, including AstraZeneca, Genentech, and Roche Pharmaceuticals, and has contributed to the development of several successful drug products.
Current Role at Asher Biotherapeutics
Christopher Del Nagro serves as the Head of Translational Science and Biomarkers at Asher Biotherapeutics. He has held this position since 2021, contributing to the company's focus on advancing therapeutic solutions. His role involves overseeing the translational science efforts and biomarker development, which are critical for the progression of drug candidates through clinical trials.
Previous Experience in Biopharmaceuticals
Del Nagro has extensive experience in the biopharmaceutical industry, having worked in various capacities at leading organizations. He was a Senior Scientist at AstraZeneca from 2017 to 2019, and prior to that, he served as a Scientist II at MedImmune from 2014 to 2017. His career also includes roles at Exelixis as Director of Translational Medicine and Genentech as Senior Scientific Researcher, where he contributed to significant drug development projects.
Educational Background and Qualifications
Christopher Del Nagro holds a Doctor of Philosophy (Ph.D.) in Biology from UC San Diego, which he completed from 1999 to 2005. He also earned a Bachelor of Science (B.S.) in Biology from UC San Diego from 1992 to 1997. Additionally, he has obtained professional certificates in Clinical Research Conduct and Management, Life Science Business, and Advanced Project Management from the University of California, Berkeley, and Stanford University.
Contributions to Drug Development
Del Nagro has played a significant role in the development of several successful drug products, including Gazyva, Rituxan-Hycela, Inebilizumab, Durvalumab/Imfinizi, and Moxetumomab/Lumoxiti. His experience spans all stages of drug development, from preclinical proof of concept to Investigational New Drug (IND) applications and Biologics License Application (BLA) filings. He has also participated in clinical studies, including a phase 1a/b study of AB248.
Industry Experience and Expertise
With over 16 years of experience in the biopharmaceutical industry, Christopher Del Nagro has expertise in both biologics and small molecules. His career includes significant roles in research and development, where he has contributed to a diverse pipeline of drug candidates currently in clinical development. His work has involved collaboration across various stages of drug development, enhancing his understanding of the complexities involved in bringing new therapies to market.